
ã¢ã¡ãªã«ã®HPVã¯ã¯ãã³è£å€è³æãã¡ã«ã¯ç€Ÿã®ç€Ÿå ã¡ãŒã«2ãæ¥æ¬ã®æ¿èªå¯©æ»ã§ã®é èœå·¥äœ
SNSã§ã¯ãHPVã¯ã¯ãã³ã®è¬å®³ã§éšãã§ããã®ã¯æ¥æ¬ã ãã ããšãã人ãããŸãããä»åœã§ã蚎èšã¯èµ·ããŠããŸããã¢ã¡ãªã«ã§ã¯6æã«å€§ããªåãããããçŽ200ä»¶ãã£ãHPVã¯ã¯ãã³ã«é¢ãã蚎èšããŸãšããŠã補è¬äŒç€ŸïŒã¡ã«ã¯ç€ŸïŒãçŽ5000äžãã«ïŒçŽ80ååïŒãæ¯æã£ãŠåè§£ããããšã«ãªã£ãããã§ãããã®äžã®1人ãJennifer Robiããã®èšŽèšã¯å€§ããªæå³ããã£ãã®ã§ããããã®èšŽèšãåè§£ãšãªããŸãããRobiããã®è£å€è³æããã¯æ§ã ãªããšãæããã«ãªã£ãŠããã®ã§ãå°ããã€æãèµ·ããããšæããŸãããã®èšäºã¯ã4æ¬ç®ã§ãã
æ¥æ¬ã®PMDAããã®åãåãã
ååãŸã§ã®èšäºã
HPVã¯ã¯ãã³ãã¬ãŒãã·ã«ããã¬ãŒãã·ã«9ïŒæ¥æ¬ã§ã¯ã·ã«ã¬ãŒã9ïŒãã®è£œé å ã§ããã¡ã«ã¯ç€Ÿã¯ãå米以å€ã§ã¯MSD (Merck Sharp and Dohme) ãšãã瀟åã§ããžãã¹ãè¡ã£ãŠããã®ã§ãæ¥æ¬ã§ã¯MSDã§ãã
Robiãããéãã®äžã§åŸãæ å ±ã¯ãè£å€è³æãšããŠäžèšã§ãå ¬éãããŠããŸãã
ãããã®è³æã¯èšŽèšã«åã€ããã«èšŒæ ãšããŠæåºããããã®ã§ãããé°è¬è«ã§ãããã§ããããŸããã
ã¢ã¡ãªã«ã®è£å€è³æã§ã¯ãæ¥æ¬ã§ã·ã«ã¬ãŒã9ïŒæ²»éšè¬V503ïŒã®æ¿èªå¯©æ»ãè¡ãããŠãããšãã«ã審æ»ãè¡ã£ãŠããPMDAããåãåããããã£ãããšã瀟å
ã¡ãŒã«ã®ãããšãã§æããã«ãªã£ãŠããŸãã
å°éçãªå 容ãªã®ã§ç¿»èš³ãµã€ãã䜿ããŸãããèš³ãééããªã©ããããããããŸãããããèŠã€ããŸããããã³ã¡ã³ãã§ãææãã ããã
Exhibit 14 to Bijan Declaration - Email RE: V503 PMDA clinical inquiry released ãã
2016幎5æ13æ¥
æ¥æ¬ã®PMDAãããäžèšã«ã€ããŠãã詳ããæ å ±ãã»ãããšããé£çµ¡ããã£ãããã§ãã

ååã¯3åç®æ¥çš®180æ¥ç®ããåŸã«èµ·ããåŠåš ãšé¢é£ããäºè±¡ã«ã€ããŠããããŠåŸåã¯7äŸã®æå®³äºè±¡ã«ã€ããŠæžãããŠããŸããã詳ããæ å ±ãã»ããããšåãåãããæ¥ãããããšã¯ã審æ»ã«ãšã£ãŠéèŠãªæå®³äºè±¡ã ããã ãšæããŸãã
å¥ã®ã¡ãŒã«ã§ã¯ããã®ãã¡3äŸã«ã€ããŠè¿ä¿¡ããããšããŠããã®ã§ãããèšèã®éžã³æ¹ã§äºå®ãé èœããããšããŠããããšãããããŸãã
Exhibit 12 - RE: [Please advise for response#2; ASAP][V503] Clinical inquiries released on Jun 14thããã
2016幎6æ23æ¥


ãããã3äŸã®è¢«éšè ã¯ãããããæåŸã®ã¯ã¯ãã³æ¥çš®ããæ°å¹ŽãçµéããåŸã®æçµæ¥é¢æã«ãåœè©²äºè±¡ã«ã€ããŠåããŠèšºæãããããã§ãããã®ãããèšåºããŒã¿ããŒã¹ã«å ¥åãããçºçŸæ¥ã¯ãäºè±¡ã®å®éã®çºçŸæ¥ãåæ ããŠããªãå¯èœæ§ããããŸãããšæžãããŠããŸããã€ãŸãã蚺æãããã®ãæ¥çš®ããæ°å¹ŽåŸã§ãã£ãŠãçºçããã®ã¯ãã£ãšåã§ããããšãã¡ãŒã«ããããããŸãã
AN 71508: 2013幎11æ1æ¥ïŒ3åç®æ¥çš®åŸ1389æ¥ç®ïŒã被éšè ã¯äœäœæ§é »èçå矀ïŒPOTSïŒãšèšºæãããã ããããè©ŠéšæéäžïŒ3åç®æ¥çš®åŸ250æ¥ç®ãã2013幎10æ10æ¥ã®æçµæ¥é¢æ¥ãŸã§ïŒãæ£è ã¯æ§ã ãªçç¶ãåãå§ãããã®äžéšã¯POTSã®çç¶ãšããŠç¥ããããã®ã§ãã£ãã
â»PMDAããã¯ãPOTSã¯èµ·ç«æ§é »èçå矀ãšèš³ãããŠããŸãã
AN 19756: 2013幎8æ22æ¥ïŒ3åç®æ¥çš®åŸ1576æ¥ç®ïŒã被éšè ã¯éç çãšèšºæãããã被éšè ã¯åŠæ æã䞻蚎ãšããŠç¡ç ã¯ãªããã¯ã«ç޹ä»ãããã2013幎6æ2æ¥ã«åã¯ãªããã¯ã§çµå€ç¡ç ããªã°ã©ãæ€æ»ã宿œããã2013幎8æ22æ¥ã«éç çãšã®èšºæã被éšè ã«å ±åãããã ãããã2010幎4æ20æ¥ã«æ£è ã¯åŠæ æïŒNSAEïŒãçµéšããã2010幎ãã2013幎ã®è©Šéšè¿œè·¡æéäžãåŠæ æã¯æªåããïŒ3åç®æ¥ç𮿥ã¯2009幎4æ29æ¥ïŒã
AN 71686: 2013幎11æ6æ¥ïŒ3åç®æ¥çš®åŸ1402æ¥ç®ïŒã被éšè ã¯èµ·ç«äžèçãšèšºæãããããããã2009幎10æ15æ¥ïŒ2åç®æ¥çš®åŸ31æ¥ç®ã3åç®æ¥çš®åïŒã«ãæ£è ã¯èµ·ç«äžèçïŒNSAEïŒãçµéšããŠããã
NSAE ã¯ãnon-serious adverse eventïŒééç¯€ãªæå®³äºè±¡ïŒã®ããšã ãšæããŸããAN 19756ã®äºäŸã§ã¯ãæåã¯éé節ã ã£ããšããŠããæªåããçµæãéé節ãšã¯èšããªãçç¶ã«ãªã£ãŠããã®ã§ã¯ãªãã§ãããããã
POTSã¯ãåååãäžããããã¥ã¡ã³ã¿ãªãŒã«åºæŒããŠããçç¶ãã¡ã«èµ·ããŠããçç¶ã§ãæ¥æ¬ã®ååãããã¡ãšãéãªãçç¶ã§ãã
å¥ã®ã¡ãŒã«ã«ã¯ãPMDAãžã®åçæ¡ã瀺ãããŠããŸãã
2016幎6æ27æ¥

ãPMDAã«çå¿µãæ±ãããªãããã«ã¯ãçŸæç¹ã§ãããæåã®åçã§ãããšèããããŸãããšæžãããŠããŸãã
åçæ¡ã«ã¯ãã3ã€ã®äºè±¡ãã¹ãŠã«ã€ããŠãå ±åãè¡ã£ãæ²»éšæ åœå»åž«ã¯ã¯ã¯ãã³ãšã®é¢é£æ§ãèªããŸããããæ²»éšè¬ãšã®é¢é£æ§ã¯äœããšèããããŸãããã®æ ¹æ ã¯ãæçµã¯ã¯ãã³æ¥çš®ããéç¯€ãªæå®³äºè±¡ïŒSAEïŒçºçŸãŸã§ã®æéã§ãã被éšè ã¯æçµæ¥é¢åŸãããªãã¡æçµã¯ã¯ãã³æ¥çš®ããæ°å¹Žãçµéããæç¹ã§åœè©²äºè±¡ãšèšºæãããŸããããšæžãããŠããŸãã
ããã«ãæ²»éšæ åœå»åž«ã¯ãHPVã¯ã¯ãã³ã®æœåšçãªæå®³äºè±¡ã«é¢ããå°å ã®ã¡ãã£ã¢ãã£ã³ããŒã³ãåããŠã被éšè ããåœè©²äºè±¡ãå ±åããããšè¿°ã¹ãŠããŸããæå®³äºè±¡ïŒAEïŒã®å ±åã¯ã詊éšã«é¢äžããŠããªãå»åž«ããã®å ±åã«åºã¥ãå°å ã®ä¿å¥åœå±ã«ãã£ãŠä¿ããããã®ã§ãããããã¯ãããã³ã«ã«èšèŒãããå®å šæ§æ å ±ã®åéæé ããéžè±ããæç¶ãã§ããããšãèšã£ãŠããŸãã
ãããªèª¬æã§ãçããã¯çŽåŸã§ããŸããïŒ
ãããå®éã¯ã蚺æãããã®ã¯æ¥çš®ããæ°å¹ŽåŸã§ãããæ²»éšã®æéäžã«ãã§ã«çºçããŠããã®ã§ããã蚺æããšããèšèãããŸãå©çšããŠãåã§ã¯ãªãã®ãªã®ãªã®èª¬æãããŠããŸãã
補è¬äŒç€Ÿãèšåºè©Šéšã®çµæã«ã€ããŠãã蚺æããšãçºçŸããšããèšèãå©çšããŠããããªé èœãããŠããã®ã§ããããã
æ¥æ¬ã®å¯©æ»å ±åæž
ãã®é èœå·¥äœãã©ããªã£ãããæ¥æ¬ã®å¯©æ»å ±åæžã確èªããŸããã審æ»å ±åæžã¯äžèšã§å ¬éãããŠããŸãã
審æ»å ±åæžããã

ãŸããæåã«æžãããŠããåŠåš ã«é¢ããäºè±¡ã¯ãäžèšã«æžãããŠããéšåã ãšæããŸããä»ã®éšåã§é èœå·¥äœãè¡ãããŠããããšãããããšããããã®å ±åãã©ããã£ãŠå æé¢ä¿ãåŠå®ããã®ãæ°ã«ãªããŸãã
ãããŠã3ã€ã®äºäŸã«é¢ããéšåã¯ããããããã®éšåã ãšæããŸãã
24ããŒãž

éç çãšèµ·ç«æ§é »èçå矀ã¯ãã3幎以äžçµéããŠããçºçŸããå¯åå¿ã§ããããšæžãããŠããŸããã蚺æãã§ã¯ãªãããçºçŸãã§ãã
éèŠãªã®ã§ãå床確èªããŸãã
AN 71508:
On 01-Nov-2013 (1389 days post-dose 3), the subject was diagnosed with postural orthostatic tachycardia syndrome(POTS).
However during study period(from 250 days post-dose3 to her last study visit on 10-Oct-2013), the patient started to develop various symptoms, some of these are known as symptoms of POTS.
AN 19756:
On 22-Aug-2013 (1576 days post-dose 3), the subject was diagnosed with hypersomnia. The subject was referred to a sleep clinic for tredness. Polysomnography was done on 2-Jun-2013 at the sleep clinic, and on 22-Aug-2013, the diagnosis of hypersomnia was reported to the subject.
However, on 20-APR-2010 patient experienced tiredness (NSAE). Between 2010 and 2013 the tiredness got worse during study follow-up period (Her third dose was 29-Apr-2009).
ãthe subject was diagnosedãã¯ã蚺æããããã§ããããçºçŸãããã§ã¯ãããŸãããã詊éšäžã«çç¶ã¯çºçŸããŠãããã3幎以äžçµéããŠãã蚺æãããå¯åå¿ã§ããããäºå®ãªã®ã«ãé èœå·¥äœã«ãã£ãŠäºå®ãããããããŠããŸã£ãã®ã§ãã
ããã«ãã®é èœå·¥äœã¯ãå¿å®¹æ§ã«ã€ããŠã倧ãã圱é¿ããããšãããããŸãã

ãæ¬å€ã® 3 åç®æ¥çš®åŸ 3 幎以äžãçµéããŠããçºçŸãã 001 詊éšã® 2 äŸ 2 ä»¶ïŒéç çãèµ·ç«æ§é »èçå矀ïŒãé€ããå埩åã¯è»œå¿«ã確èªãããŠããããšãšãEMAã«ããäžè¬éå£ã§ã®çºçŸå²åããç¹æã®æžå¿µã¯èªããããªããšèããããšæžãããŠããŸãã
ããã©ããPMDAãåãåããã2äŸã¯ãèšåºè©Šéšæéäžã«çºçŸããŠã3幎çµã£ãŠãå埩ããŠããªãããããæªåããŠããã®ã§ãããã®äºå®ãç¥ã£ãäžã§ãPMDAã¯ãç¹æã®æžå¿µã¯èªããããªãããšçµè«ã¥ããã§ããããã
ãããŠEMAããåœæ°ãã補è¬äŒç€Ÿå¯ãã§ããããšã¯åã åã®èšäºãããããããŸãïŒäžèšåç §ïŒã
ãã®2ã€ãæ ¹æ ã«ãç¹æã®æžå¿µã¯èªããããªãããšããã®ã¯ãæ¬åœã«å®å šã ãšç¢ºèªã§ãããšã¯èšããªããšæããŸãã
ããã«ã远跡äžèœã1äŸãã£ããšæžãããŠããŸãããèšåºè©Šéšãªã®ã«ãªã远跡äžèœã«ãªã£ãã®ã§ããããã远跡äžèœã®çç±ãç¥ãããã§ããã¬ãŒãã·ã«ãã远跡äžèœãç°åžžã«å€ãã£ãã®ã§æ°ã«ãªããŸãïŒäžèšåç §ïŒã
ãããªæ¿èªå¯©æ»ã§ãå®å
šã確èªã§ããŠãããšæããŸããïŒ
æšé²æŽŸã®äººãã¡ã¯ãããã§ãå®å
šã ãšäººã«å§ããããã®ã§ããããã
ã§ã¯å€äŒã¿ãå©çšããŠãç£å©Šäººç§å»ããããªãã©ã·ãäœã£ãŠæ¥çš®ãä¿ããã¹ããããŠããŸããã

ãå°æ¥ã®å€¢ããããããããšããããããªãããã«ãããšã¯ãããã¯ãªã§ããæ¥çš®ããçµæãå°æ¥ã®å€¢ãããããããšã諊ãã人ãäžçäžã«ããŠã蚎èšãèµ·ããŠããã®ã«ãå¯äœçšã«ã€ããŠå šãè§ŠããŠããŸãããã€ã³ãã©ãŒã ãã³ã³ã»ã³ããç¡èŠãããã®ãããªãã©ã·ãäœã£ãŠãæ¥çš®ãå§ããŠããå»åž«ãä¿¡é Œã§ããã§ãããããäœã®äžã«å»è¬åãå ¥ããããšã«å¯ŸããŠããŸãã§ãå€äŒã¿ã«ã¯ã©ãžãªäœæã«è¡ããïŒããšãããã©ã·ã®ãããªããæ°è»œãªæèŠã§å§ããŠããå»åž«ãããã¯ã¯ãã³æ¥çš®ã人ã®åœã«é¢ãããšããéããäŒãã£ãŠããã§ããããã
æšé²æŽŸã®å»åž«ã¯ãããæ¥çš®åŸã«ååãããã¡ã®ãããªé節ãªçç¶ãåºãŠããå©ããŠã¯ãããŸãããå€ãã®å»åž«ã¯ããå¯åå¿ãªããŠãããŸãããã粟ç¥ç§ã«è¡ã£ãŠãã ããããšèšãã ãã§ããããã¯å®éã«ãå€ãã®ååãããã¡ãçµéšããŠããããšã§ãããåœãéžå®ããååå»çæ©é¢ã§ããã¡ããšèšºå¯ããŠããããŠããŸããïŒäžèšåç §ïŒã
ãã¡ããšç ç©¶ã調æ»ãé²ããæ¬åœã®æå³ã§å®å šã確èªããããã«ã¯ãè£å€ã§å蚎ããªããã°ãªããŸãããå蚎ããããã«ã¯ãäžè«ã®åŸæŒããå¿ èŠã§ãã
è£å€ã®ç®çãªã©ã«ã€ããŠã¯ãäžèšã«ã詳ããæžãããŠããŸãã
è£å€æå®
ååŽçå®
å€äŒã¿äžã«ã¯ãå šåœåå°ã§ååãããã¡ã®ã声ããèããã€ãã³ããããããéå¬ãããŸãããªã³ã©ã€ã³åå ã§ãããã®ãããã®ã§ããŸãã¯ãååãããã¡ã«èµ·ããŠãããäºå®ããèããŠã¿ãŠãã ããã
HPVã¯ã¯ãã³åé¡ã€ãã³ãã¹ã±ãžã¥ãŒã«







HPVã¯ã¯ãã³åé¡ãæ¢ç©¶å°èª¬ã«ããŠã¿ãŸããïŒ